Tango Therapeutics (TNGX) Liabilities and Shareholders Equity (2020 - 2026)

Tango Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $435.8 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 58.87% year-over-year to $435.8 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 3.18% decrease from a year earlier, with the FY2025 full-year figure at $398.7 million, up 25.97% from the prior year.
• Liabilities and Shareholders Equity rose to $435.8 million in Q1 2026 per TNGX's latest filing, from $398.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $471.5 million in Q1 2022 and bottomed at $210.1 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $402.6 million (2023), against an average of $379.3 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 180.23% in 2022 and plunged 40.37% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $436.5 million in 2022, then retreated by 7.77% to $402.6 million in 2023, then fell by 21.38% to $316.5 million in 2024, then gained by 25.97% to $398.7 million in 2025, then climbed by 9.31% to $435.8 million in 2026.
• Per Business Quant, the three latest TNGX Liabilities and Shareholders Equity figures stand at $435.8 million (Q1 2026), $398.7 million (Q4 2025), and $210.1 million (Q3 2025).